From: Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines
Cell Lines | Cell Cycle phase | CT | 1 μM | 3 μM | 5 μM |
---|---|---|---|---|---|
HT-29 | G0/G1 | 77.14 ± 0.02 | 84.37 ±0.10* | 40.29 ± 5.40** | 46.07 ± 0.68** |
S | 8.31 ± 0.45 | 4.40 ± 1.06 | 19.59 ± 4.02* | 9.30 ± 0.47 | |
G2/M | 13.41 ± 0.70 | 10.17 ± 0.32* | 34.72 ± 0.86** | 40.03 ± 0.38** | |
T84 | G0/G1 | 28.14 ± 0.01 | 41.84 ± 1.53** | 32.97 ± 0.28** | 36.06 ± 0.06** |
S | 17.86 ± 1.03 | 17.52 ± 0.05 | 18.85 ± 0.20 | 19.39 ± 3.93 | |
G2/M | 43.67 ± 0.01 | 38.51 ± 1.48* | 45.64 ± 0.51 | 50.23 ± 0.01* | |
MCF-7 | G0/G1 | 17.10 ± 1.56 | 22.45 ± 0.78* | 19.30 ± 0.99* | 20.20 ± 1.13* |
S | 26.25 ± 0.35 | 26.95 ± 0.07 | 24.15 ± 1.20 | 22.95 ± 1.48 | |
G2/M | 40.50 ± 0.71 | 33.85 ± 1.20* | 30.20 ± 0.28* | 24.95 ± 0.07** | |
A549 | G0/G1 | 65.82 ± 2.62 | 63.48 ± 4.47 | 66.62 ± 3.59 | 61.54 ± 1.14 |
S | 14.10 ± 3.29 | 13.61 ± 2.64 | 11.55 ± 2.67 | 14.90 ± 0.36 | |
G2/M | 21.31 ± 0.83 | 24.56 ± 2.21* | 23.40 ± 1.41* | 25.18 ± 0.73* | |
DU145 | G0/G1 | 56.24 ± 7.90 | 46.12 ±15.97 | 25.99 ± 7.43** | 16.76 ± 1.61** |
S | 12.19 ± 3.79 | 16.36 ± 3.25 | 8.02 ± 2.14 | 8.57 ± 1.70 | |
G2/M | 29.89 ± 3.99 | 31.26 ± 5.85 | 56.97 ± 6.24** | 55.93 ± 5.53** | |
HepG2 | G0/G1 | 59.68 ± 0.09 | 47.17 ± 4.18* | 23.23 ± 0.59** | 19.91 ± 5.82** |
S | 12.33 ± 0.86 | 10.68 ± 2.74 | 7.04 ± 0.52* | 7.91 ± 2.71 | |
G2/M | 26.39 ± 0.41 | 36.63 ± 7.25* | 57.84 ± 1.53** | 59.49 ±7.52** | |
Hela | G0/G1 | 62.42 ± 0.01 | 62.48 ± 0.08 | 63.49 ± 1.33 | 63.59 ± 2.26 |
S | 10.35 ± 0.18 | 9.02 ± 0.59 | 8.19 ± 0.24 | 7.86 ± 0.33 | |
G2/M | 25.87 ± 0.27 | 26.36 ± 0.28 | 24.90 ± 0.32 | 26.19 ± 0.12 | |
Hep-2 | G0/G1 | 62.78 ± 4.35 | 69.50 ± 4.65 | 63.39 ± 0.07 | 61.83 ± 7.97 |
S | 18.73 ± 2.57 | 12.72 ± 3.64 | 16.79 ± 0.73 | 17.77 ± 5.70 | |
G2/M | 20.66 ± 1.48 | 18.65 ± 1.92 | 20.31 ± 0.72 | 20.53 ± 2.57 |